Imunon (IMNN) Other Non-Current Liabilities (2011 - 2022)
Imunon's (IMNN) quarterly Other Non-Current Liabilities came in at $5.4 million in Q3 2022, down 26.54% YoY from $7.3 million in Q3 2021, and little changed on a QoQ basis from $5.4 million in Q2 2022.
Imunon (IMNN) Other Non-Current Liabilities (2011 - 2022) Analysis & Trends
Imunon (IMNN) has 12 years of Other Non-Current Liabilities data on file, last reported at $5.4 million in Q3 2022.
- Quarterly Other Non-Current Liabilities fell 26.54% year-over-year to $5.4 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $5.4 million (down 26.54% YoY) and the FY2021 annual result came in at $5.4 million, down 23.11% from the prior year.
- Other Non-Current Liabilities was little changed at $5.4 million in Q3 2022, from $5.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $7.3 million in Q3 2021 to a low of $63278.0 in Q4 2018.
- A 5-year average of $4.9 million and a median of $5.8 million in 2020 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2018 — Other Non-Current Liabilities tumbled 99.5% — and 2019, when it soared 8935.86%.
- Tracing IMNN's Other Non-Current Liabilities over 5 years: stood at $63278.0 in 2018, then soared by 8935.86% to $5.7 million in 2019, then rose by 22.74% to $7.0 million in 2020, then decreased by 23.11% to $5.4 million in 2021, then changed by 0.0% to $5.4 million in 2022.
- The last three Other Non-Current Liabilities figures came in at $5.4 million (Q3 2022), $5.4 million (Q2 2022), and $5.4 million (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 5.40 Mn |
| Jun 30, 2022 | 5.40 Mn |
| Mar 31, 2022 | 5.40 Mn |
| Dec 31, 2021 | 5.40 Mn |
| Sep 30, 2021 | 7.35 Mn |
| Jun 30, 2021 | 7.09 Mn |
| Mar 31, 2021 | 7.17 Mn |
| Dec 31, 2020 | 7.02 Mn |
| Sep 30, 2020 | 7.12 Mn |
| Jun 30, 2020 | 6.02 Mn |
| Mar 31, 2020 | 5.76 Mn |
| Dec 31, 2019 | 5.72 Mn |
| Sep 30, 2019 | 5.82 Mn |
| Jun 30, 2019 | 5.90 Mn |
| Mar 31, 2019 | 5.78 Mn |
| Dec 31, 2018 | 63,278.00 |
| Sep 30, 2018 | 65,701.00 |
| Jun 30, 2018 | 68,755.00 |
| Mar 31, 2018 | 70,232.00 |
| Dec 31, 2017 | 12.54 Mn |